AU2009216067B2 - Composition for modulating stem cell growth with prostaglandins - Google Patents

Composition for modulating stem cell growth with prostaglandins Download PDF

Info

Publication number
AU2009216067B2
AU2009216067B2 AU2009216067A AU2009216067A AU2009216067B2 AU 2009216067 B2 AU2009216067 B2 AU 2009216067B2 AU 2009216067 A AU2009216067 A AU 2009216067A AU 2009216067 A AU2009216067 A AU 2009216067A AU 2009216067 B2 AU2009216067 B2 AU 2009216067B2
Authority
AU
Australia
Prior art keywords
alkyl
hydroxy
halogen
cyclo
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009216067A
Other languages
English (en)
Other versions
AU2009216067A1 (en
Inventor
Sachiko Kuno
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2009216067A1 publication Critical patent/AU2009216067A1/en
Application granted granted Critical
Publication of AU2009216067B2 publication Critical patent/AU2009216067B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2009216067A 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins Ceased AU2009216067B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2971308P 2008-02-19 2008-02-19
US61/029,713 2008-02-19
PCT/JP2009/053474 WO2009104807A1 (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins

Publications (2)

Publication Number Publication Date
AU2009216067A1 AU2009216067A1 (en) 2009-08-27
AU2009216067B2 true AU2009216067B2 (en) 2014-02-13

Family

ID=40602552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009216067A Ceased AU2009216067B2 (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins

Country Status (16)

Country Link
US (2) US8871752B2 (enExample)
EP (2) EP2656845A1 (enExample)
JP (1) JP2011512323A (enExample)
KR (1) KR20100119803A (enExample)
CN (2) CN102014921A (enExample)
AR (1) AR073158A1 (enExample)
AU (1) AU2009216067B2 (enExample)
BR (1) BRPI0907831A2 (enExample)
CA (1) CA2715486A1 (enExample)
IL (1) IL207652A0 (enExample)
MX (1) MX2010009131A (enExample)
NZ (1) NZ587348A (enExample)
RU (1) RU2010138603A (enExample)
TW (1) TW200942614A (enExample)
WO (1) WO2009104807A1 (enExample)
ZA (1) ZA201006125B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533445A1 (en) * 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
KR101171912B1 (ko) 2010-11-29 2012-08-07 기아자동차주식회사 밸브브릿지 일체형 가변 밸브 액츄에이터
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US20140371304A1 (en) * 2013-06-13 2014-12-18 Sucampo Ag Method for suppressing tumorigenicity of stem cells
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
AU2018280264B2 (en) 2017-06-09 2024-07-11 Myoforte Therapeutics, Inc. Compositions and methods for preventing or treating muscle conditions
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080547A1 (en) * 2005-01-28 2006-08-03 Aisin Aw Co., Ltd. Image recognizing apparatus and method, and position determining apparatus, vehicle controlling apparatus and navigation apparatus using the image recognizing apparatus or method
WO2007070964A1 (en) * 2005-12-22 2007-06-28 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
WO2007112084A2 (en) * 2006-03-24 2007-10-04 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
AU2001239551B8 (en) * 2000-03-24 2005-11-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
EP1853271B1 (en) * 2005-03-04 2010-12-01 Sucampo AG Method and composition for treating peripheral vascular diseases
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
FI20075417A0 (fi) 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080547A1 (en) * 2005-01-28 2006-08-03 Aisin Aw Co., Ltd. Image recognizing apparatus and method, and position determining apparatus, vehicle controlling apparatus and navigation apparatus using the image recognizing apparatus or method
WO2007070964A1 (en) * 2005-12-22 2007-06-28 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
WO2007112084A2 (en) * 2006-03-24 2007-10-04 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria

Also Published As

Publication number Publication date
WO2009104807A1 (en) 2009-08-27
MX2010009131A (es) 2010-12-06
RU2010138603A (ru) 2012-03-27
CN102014921A (zh) 2011-04-13
BRPI0907831A2 (pt) 2017-04-11
IL207652A0 (en) 2010-12-30
CA2715486A1 (en) 2009-08-27
KR20100119803A (ko) 2010-11-10
TW200942614A (en) 2009-10-16
NZ587348A (en) 2012-04-27
JP2011512323A (ja) 2011-04-21
EP2656845A1 (en) 2013-10-30
US20150005381A1 (en) 2015-01-01
AU2009216067A1 (en) 2009-08-27
AR073158A1 (es) 2010-10-20
US20090209643A1 (en) 2009-08-20
CN104248638A (zh) 2014-12-31
ZA201006125B (en) 2011-05-25
US8871752B2 (en) 2014-10-28
EP2303278A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
AU2009216067B2 (en) Composition for modulating stem cell growth with prostaglandins
AU2007225798A1 (en) Aqueous composition
JP2004519412A (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
RU2548762C2 (ru) Способ и композиция для лечения дегенерации желтого пятна
US20080207759A1 (en) Method for protecting mitochondria
US20100305203A1 (en) Method for modulating claudin mediated functions
EP3035925A1 (en) Method for treating neuropathic pain
US8569279B2 (en) Method for modulating claudin mediated functions
WO2016067620A1 (en) Method and composition for treating nonerosive reflux disease
EP3008171A1 (en) Method for suppressing tumorigenicity of stem cells
US20120277299A1 (en) Method for modulating ion transporter
EP2841065A1 (en) Method for treating irritable bowel syndrome with diarrhea
JP2010126475A (ja) 白髪防止剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired